
Table of Contents

List of Abbreviations	i
Symbols.....	iii
List of Figures.....	iv
List of Tables	vi
Preface.....	vii
1. Introduction	1
2. Literature review	9
2.1 Pathophysiology of hemorrhoids	9
2.3 Classification of hemorrhoids:	11
2.4 Prevalance of hemorrhoids:.....	11
2.5 Management of hemorrhoids:	13
2.6 Medical treatment:.....	14
2.7 Plant profile.....	18
2.7.1 Distribution.....	18
2.7.2 Classification	19
2.7.3 Classical & Common names.....	19
2.7.4 Synonyms	19
2.7.5 Traditional uses reported for <i>Blumea lacera</i> (Burm. f.) Dc.....	20
2.7.6 Chemical constituents reported in <i>Blumea lacera</i> (Burm. f.) Dc.....	25
2.7.7 Reported pharmacological uses of <i>Blumea lacera</i> (Burm. f.) Dc.....	30
3. Objective of Study	35
4. Anti-haemorrhoid activity of ethanolic extract.....	39
4.1 Experimental work	39

4.1.1 Collection of plant material and authentication.....	39
4.1.2 Extraction process optimization using BBD towards response surface	39
4.1.3 Check point analysis (validation of method).....	41
4.1.4 <i>In vitro</i> Anti-inflammatory activity	41
4.1.5 Experimental Animals	42
4.1.6 Acute oral toxicity study.....	42
4.1.7 Anti-haemorrhoid activity	43
4.1.8 <i>In vivo</i> antioxidant studies	46
4.1.9 Statistical analysis:	47
4.2 Results.....	48
4.2.1 Extraction process and its optimization.....	48
4.2.2 Checkpoint analysis (validation of method).....	53
4.2.3 Standardization of EBL using HPLC	53
4.2.4 <i>In vitro</i> Anti-inflammatory activity	54
4.2.5 Acute oral toxicity of EBL:	54
4.2.6 Anti-haemorrhoid activity	54
4.2.7 <i>In vivo</i> antioxidant studies	59
4.3 Discussion	60
4.4 Conclusion.....	63
5. Development of silver nanoparticles	67
5.1 Experimental works.....	67
5.1.1 Materials	67
5.1.2 Extract preparation and fractionation	67
5.1.3 Quantitative phytochemical estimation	68
5.1.4 <i>In vitro</i> antioxidant activity	71

5.1.5 <i>In vitro</i> anti-inflammatory activity	74
5.1.6 Standardization of fractions from EBL and quantification of phytoconstituents by HPTLC.....	75
5.1.7 Standardization of EAF by HPLC	76
5.1.8 Molecular docking studies on endothelin 1, AMPK and cytokines (TNF α and IL-6)	77
5.1.9 Synthesis of silver nanoparticles (PLSNPs)	77
5.1.10 Process optimization.....	78
5.1.11 Check point analysis (validation of method).....	80
5.1.12 Characterization of PLSNPs.....	81
5.1.13 Estimation of entrapment efficiency (EE) and drug loading capacity (DLC).....	83
5.1.14 <i>In vitro</i> release profile of PLSNPs.....	83
5.1.15 Antibacterial activity	84
5.1.15 Statistical analysis:	85
5.2 Results	85
5.2.1 Quantitative phytochemical estimation	85
5.2.2 <i>In vitro</i> antioxidant activity of EBL fractions	86
5.2.3 <i>In vitro</i> anti-inflammatory activity of fractions from EBL.....	88
5.2.4 Standardization of fractions from EBL and quantification of phytoconstituents by HPTLC.....	89
5.2.5 Standardization of EAF by HPLC	90
5.2.6 Molecular docking studies on Endothelin 1 and cytokines (TNF α and IL-6).....	91
5.2.7 Synthesis and confirmation of PLSNPs.....	95
5.2.8 Process optimization.....	95
5.2.9 Checkpoint analysis (validation of method).....	99
5.2.10 Characterization of PLSNPs.....	100

5.2.10.3 TGA and DSC analysis.....	103
5.2.11 Estimation of entrapment efficiency and drug loading capacity	103
5.2.12 <i>In vitro</i> release profile of PLSNPs.....	103
5.2.13 <i>In vitro</i> antioxidant activity	104
5.2.14 <i>In vitro</i> anti-inflammatory activity of PLSNPs	105
5.2.15 Antibacterial activity	105
5.3 Discussion	107
5.4 Conclusion.....	113
6. Anti-haemorrhoid activity of silver nanoparticles.....	117
6.1 Experimental works.....	117
6.1.1 Experimental Animals	117
6.1.2 Acute and sub-acute oral toxicity study	117
6.1.3 Anti-haemorrhoid activity	118
6.1.4 <i>In vivo</i> antioxidant studies	121
6.1.5 Statistical analysis.....	121
6.2 Results	121
6.2.1 Acute and subacute oral toxicity of PLSNPs.....	121
6.2.2 Anti-hemorrhoid activity	124
6.2.3 <i>In vivo</i> antioxidant studies	126
6.3 Discussion	127
6.4 Conclusion.....	131
7. Summary.....	135
References	141
List of Publications	165